Background: Several candidate genes have been associated with obesity, but very few studies have tested more than one gene simultaneously. Methods: In this study, 15 polymorphisms in 10 candidate genes of obesity were tested for association with changes in adiposity measured over a period of 6-10 years in a maximum of 332 adult subjects with a wide range of adiposity (17.5obody mass index (BMI)o55.6 kg/m 2 ) from the Québec Family Study. Stepwise regression models were used to identify the combination of genes explaining changes in adiposity after adjustment for age (initial value), gender, initial value of the adiposity variable and duration of follow-up. Analyses were carried out in the whole sample and repeated while stratifying on age (o40 and X40 years). Results: In the whole sample, the variance in age-related adiposity changes explained by the candidate gene polymorphisms ranged from 3.1% (BMI, Po0.05) to 8.5% (fat mass (FM), Pp0.0005). The genes retained in the prediction model for changes in FM were leptin (Pp0.05), guanine nucleotide binding protein b3 (Pp0.05), adrenergic receptor b3 (Pp0.05), neuromedin b (Pp0.05) and peroxisome proliferator-activated receptor-g2 (Pp0.10). The effects of the genes were significant in both age groups, but the genes contributing to adiposity changes were different and their effects were stronger in the younger than in the older age group. Conclusion: This study suggests that models including genetic information from several candidate gene polymorphisms can significantly contribute to the changes in adiposity over time, that different genes may act at different ages and that genetic information could be useful for the identification of individuals at high risk for gaining body fat over time.
Introduction
Obesity is a complex condition involving environmental, behavioral and genetic factors as well as interactions among them. The environment has changed dramatically during the last century and the increased availability of highly palatable energy dense foods as well as a lower physical activity levels are thought to play a major role in the development of obesity. 1, 2 On the other hand, although it is accepted that the genetic pool has not evolved very much in the last century, there appear to be genes and sequence variants that define a predisposition to develop obesity. In the past 20 years, 113 candidate genes have been associated with obesity-related phenotypes in at least one study. 3 A better understanding of how these genes interact with environmental determinants of obesity is needed to help prevent weight gain and/or to improve weight loss. Very few studies have investigated the contribution of genetic factors in determining changes in adiposity. Results from twin studies have provided evidence that changes in body mass index (BMI) over time are influenced by genetic factors. 4, 5 Results from the longitudinal Québec Family
Study have also showed that there was a significant familial resemblance for changes in BMI and subcutaneous fat with heritabilities of 37 and 16%, respectively. 6 More recently, significant familial aggregation was found for 7-year changes in BMI and adiposity measured in more than 1300 subjects from 521 families with heritability estimates ranging from 12% for changes in subcutaneous fat to 45% for changes in waist circumference. 7 Despite the evidence that genetic factors play a role in determining changes in adiposity, very few studies have investigated the role of obesity candidate genes in these changes. Results from a few studies have shown that the adrenergic-b2 and leptin receptors (LEPRs), 8 glucocorticoid receptor (GCCR), 9 adipsin and adrenergic receptor-b2, 10 and neuromedin b (NMB) 11 genes were associated with adiposity changes over time. However, none of these studies considered the role of several genes analyzed simultaneously in a multigenic model, in determining adiposity changes over time.
In the present study, we tested, in a prospective study design with 6-10 years of follow-up, the hypothesis that some obesity candidate genes, when included in the same regression model, are significantly predictive of changes in adiposity over the years in adults. The presence of an association between a candidate gene and changes in adiposity could be interpreted as evidence for a gene by age interaction, a special case of gene by environment interaction. The genes and the polymorphisms retained for this study were expressed peripherally, were already associated with obesity-related phenotypes in more than five studies or were significantly associated with adiposity changes over time in prior Quebec Family Study (QFS) reports.
3,9,11

Materials and methods
Subjects
The QFS is a prospective family study designed to investigate the genetics of obesity and its comorbidities. 12 The subjects of this study were healthy male and female adults (X17.5 years) for which at least two measures of adiposity across the various phases of QFS were available (phase 1: 1978-1982; phase 2: 1990-1997; phase 3: 1995-2001 ). The mean follow-up period ranged from 6.070.9 to 10.473.4 years for waist girth (WG) and BMI, respectively. The age distribution in this QFS sample is representative of two age groups corresponding to the two generations (parents and offspring) seen in family study such as QFS. Based on age at first measure, the two age groups roughly correspond to subjects below 40 years of age (offspring generation) and those above 40 years of age (parental generation). At least two measurements of adiposity were available for BMI, sum of six skinfolds (SUM6), waist circumference, fat mass (FM) and percent body fat (PFAT) in 332, 330, 291, 273 and 273 subjects, respectively. The Laval University Ethics Committee approved the procedures of all three phases of QFS.
Measurements
Adiposity measures were obtained as described elsewhere. 12 Briefly, BMI was calculated by dividing weight (kg) by squared height (m 2 ), WG was measured midway between the suprailiac crest and the lower rib (cm), 13 subcutaneous skinfold thicknesses (SUM6) were measured with a Harpenden skinfold caliper (biceps, triceps, calf, subscapular region, abdomen and suprailiac crest), 14 body density was obtained by underwater weighing, and PFAT was estimated from body density using the Siri equation. 15 FM was derived from PFAT and body weight. Table 1 presents the genes, polymorphisms chosen, genotype frequencies, genomic localization and selected references. Theses genes were selected on the basis of three criteria: they were expressed peripherally, were already associated with adiposity-related phenotypes in more than five studies or were significantly associated with adiposity changes over time in prior QFS reports. Moreover, most of the polymorphisms retained were known to modulate the gene function (Table 1) . Among them, seven were related to energy balance and the control of food intake. They were the leptin (LEP) gene and LEPR, the GCCR gene, the adrenergic receptors a2a, b2 and b3 (ADRA2A, ADRB2 and ADRB3) genes and the NMB gene. LEP and LEPR are known to modulate food intake and energy balance 16 and are responsible for some rare monogenic forms of obesity. 3 When activated, GCCR exerts orexigenic 17 and antithermogenic effects. 18, 19 The peripheral sympathetic nervous system is a major player in the regulation of energy balance and the physiological responses to adrenaline and noradrenaline are exerted through the adrenergic receptors a and b. 20 Finally, NMB is a member of the bombesin-like peptides family mainly secreted in the brain and the gastrointestinal tract. It is known to be associated with decreases in food intake and locomotor activity 21 and was recently associated with eating behaviors and adiposity changes in QFS. 11 For this study, 11 polymorphisms within LEP, LEPR, GCCR, ADRA2A, ADRB2, ADRB3 and NMB genes were selected. Two genes involved in adipocyte differentiation and metabolism were also selected: peroxisome proliferatoractivated receptor-g 2 (PPARg2) and tumor necrosis factor-a (TNFa) genes. PPARg2 is a nuclear receptor mostly expressed in adipose tissue and plays an important role in the regulation of adipocytes differentiation and lipid metabolism. 16 The product of TNFa gene is secreted by adipocytes and decreases lipogenesis and increases lypolysis. 16 Two polymorphisms in PPARg2 and one in TNFa were chosen. Finally, the guanine nucleotide binding protein b3 (GNB3) is the b3 subunit of a G protein and is expressed in all types of cell lines tested to date. 22 The G protein is localized in the plasma membrane and mediates the response to receptor agonists. 22 Its physiological role in the development of hypertension and obesity is not fully understood, but signal
Selection of candidate genes
Candidate genes of adiposity changes L Bouchard et al transduction alteration may modulate disease susceptibility. 22 Eight out of the 10 genes that were retained in this study showed positive association with obesity-related phenotypes in more than five studies (LEP, LEPR, GCCR, ADRB2, ADRB3, PPARg2, TNFa and GNB3). 3 Altogether, 15
polymorphisms were tested.
Determination of the genotypes
Genomic DNA was extracted from permanent lymphoblastoïd cells using the proteinase K and QIAGEN Blood & Cell Culture DNA Maxi Kit. Details of markers genotyping are described elsewhere. 9, [23] [24] [25] [26] [27] [28] Briefly, all polymorphisms but NMB p.P73T were restriction fragment length polymorphism (see Table 1 for endonucleases used). NMB p.P73T was genotyped using a minisequencing technique. 11 The genotyping techniques used in the present study has a success rate of at least 90% in our laboratory.
Study design
Infrequent homozygote genotypes (less than 25 homozygotes in the whole sample) were merged with heterozygotes and the effects of the variant alleles were considered as dominant (LEPRK656N, ADRA2DraI, ADRB2BanI, ADRB3W64R, PPARGP12A and TNFA-308). All other polymorphisms were analyzed under codominant, dominant and recessive models. As the same results were obtained under all three models, only the results of the codominant model are presented.
Statistical analysis
All statistical tests were performed using SAS software (version 8.02). The dependent variables used in the prediction models were changes in BMI, SUM6, WG, FM and PFAT. A change over a given period of time (delta, D) represents the difference between the values observed between time 
; associated with cortisol levels (BclI) 34, 35 ADRA2A Chromosome 10q25 ADRA2ADraI 6.3/6.3+6.3/6.7 (30%) 6.7/6.7 (70%) Unknown (DraI)
PPARg Chromosome 3p25 PPARGP12A P/P (83%) P/A+A/A (17%) p.P12A; associated with lower binding affinity with promoter (BstUI) 39 PPARGXbaI Unknown (XbaI)
Promoter g.À308G4A, associated with enhanced secretion of TNF-a (NcoI) [40] [41] [42] 
GNB3
Chromosome 12p13 GNB3-825 C/C (50%) C/T (42%) T/T (9%) Promoter, g.À825C4T; associated with shorter splice variant expression and enhanced intracellular signal transduction (BsaJI) 22 Candidate genes of adiposity changes L Bouchard et al periods. We were having two goals when phases for followup computation were selected: (1) optimize the number of subjects available for the analyses and (2) keep follow-up periods comparable for all adiposity phenotypes. For DBMI and the SUM6 computation, only measurements from the first and the second phases of QFS were retained. The waist circumference was measured only during the second and the third phases of QFS. Therefore, only the second and the third phases were used for DWG computation. Finally, for DFM and PFAT computation a total of 194 measures were obtained from phases 1 and 2 and 79 measures were from phases 2 and 3. In order to keep follow-up differences between individuals comparable (i.e. about 6-10 years), changes between phases 1 and 3 were not computed. Paired t-tests were performed to verify if adiposity changes were significant. Analysis of covariance was used to calculate residual scores to be used in the regression models. DBMI, DSUM6, DWG, DFM and DPFAT were adjusted for gender, age at first measure, initial (time 1) value of the phenotype and duration of the follow-up (Dage). WG was further adjusted for initial BMI value and DBMI (DWGBMI). By adjusting DWG for initial BMI and DBMI, we obtain a measure of the changes in abdominal obesity (DWG) that is independent of the overall changes in adiposity. The 15 polymorphisms in the 10 candidate genes were regressed on the residual scores using a stepwise regression model. The cutoff P-value to include a polymorphism within the model was defined as Po0. 15 . Forward and backward regression procedures were also performed.
To test the effect of relatedness among family members before the computation of the residual scores, the sandwich estimator, as implemented in the SAS mixed procedure, 29, 30 was used. Only DBMI showed a marginally significant relatedness effect (P ¼ 0.05). All other dependent variables were not affected by relatedness (DSUM6, P ¼ 0.27; DWG, P ¼ 0.32; DWGBMI, P ¼ 0.87; DFM, P ¼ 0.72 and DPFAT, P ¼ 0.48). As the effect of family was only marginal for DBMI and was not significant for the other phenotypes, we have decided to use standard general linear model and not the sandwich estimator.
Results
Baseline characteristics of the subjects and adiposity changes over time are presented in Table 2 . On average, subjects were overweight at baseline. Men have less subcutaneous fat (measured by the SUM6), FM and PFAT but have a larger WG than women. The average follow-up ranged from 6.0 70.9 years for WG to 10.473.4 years for BMI and SUM6. Only the changes in subcutaneous fat measured by the SUM6 were different between men and women. In this case, women gained almost twice as much subcutaneous fat as men. Overall, the majority of subjects gained body fat over time: 76% of the subjects experience an increase in BMI, 80% an increase in SUM6, 78% an increase in WG, 83% an increase in FM and 80% an increase in PFAT. For each phenotype (D), adiposity gain was significant.
Changes in adiposity-related phenotypes were computed and adjusted for as described in the Materials and methods and submitted to a stepwise regression analysis using the 15 polymorphisms as independent variables. The results are presented in Table 3 . The covariates significantly accounted for 3.9% (P ¼ 0.012), 15% (Po0.0001), 7.5% (P ¼ 0.0003) and 19.7% (Po0.0001) of the changes in BMI, SUM6, FM and PFAT, respectively. For changes in WG, the covariates did not explain a significant proportion of the variance (1.6%; P ¼ 0.334). However, when WG changes was adjusted for BMI (WGBMI), covariates significantly accounted for 81.5% of the variance, changes in BMI was the most important covariate contributor (R 2 ¼ 0.755; Po0.0001).
Three to five genes were found to predict significantly adiposity changes over time and they accounted for 3.1-8.5% of the residual variance. For changes in BMI, ADRA2A-DRAI, PPARGXbaI and NMBP73T polymorphisms were retained in the model. Although the overall P-value was significant (R 2 ¼ 3.1%; P ¼ 0.018), none of these genes showed Pp0.05. For DSUM6, NMBP73T, PPARGXbaI, GNB3-825, ADRA2ADRAI and TNFA-308 (R 2 ¼ 5.6%; P ¼ 0.003) were retained in the final model. The NMBP73T and PPARGXbaI polymorphisms significantly explained 3.2 out of 5.6% of the residual variance (Po0.05). Five genes Candidate genes of adiposity changes L Bouchard et al Table 3 Multiple regression analyses of polymorphisms associated with adiposity gain ADRB3W64R, GNB3-825 and NMBP73T. For DFM, all four showed Po0.05, whereas only LEP and ADRB3 polymorphisms showed Po0.05 for DPFAT. The LEP-38 polymorphism showed the strongest association explaining 3.3% of the variance in percentage body fat changes over time (P ¼ 0.004). In addition to these four genes, PPARGP12A and ADRB2Q27E polymorphisms were also retained in prediction models for changes in FM and PFAT, respectively. The stepwise regression analyses were repeated by stratifying on age group at first measure (Table 3) . Overall, the genes accounted for a higher amount of residual variance in the younger (o40 years) group than in the older (X40 years) group. In the younger group, the genes accounted for 6.9, 10.4 10.3, 7.9, 14.2 and 11.2% of the variance in changes of BMI, SUM6, WG, WGBMI, FM and PFAT, respectively, whereas in the older group the corresponding values were 0, 2.9, 5.0, 7.1, 6.8 and 5.4%. For DBMI, DSUM6, DWG and DFM, the genes that were found significantly (Pp0.05) predictive in these models in the younger group were also predictors of adiposity changes in the whole sample. For DWGBMI, none on the genes retained in the whole sample was retained in this age group. However, PPARXBAI and GNB3-825 polymorphisms were found to significantly predict changes in WG when adjusted for BMI (DWGBMI). For DPFAT, in addition to LEP-38 polymorphism, TNFA-308 variant was found to significantly predict changes in body fatness (DPFAT). In the older group, none of the genes that significantly (Pp0.05) predicted changes in adiposity were found to be associated with these phenotypes except for the LEP-38 variant in the DFM model. However, new polymorphisms, LEPK109R, PPARGP12A and ADRB2Q27E, were found to significantly predict DSUM6, DWGBMI and DPFAT, respectively.
Forward and backward regression procedures were also performed to confirm results from the stepwise selection in the whole sample. All polymorphisms found to be significantly predictive of adiposity changes using the stepwise regression procedure were also found significantly predictive using the forward and the backward regression procedures. However, the backward procedure identified other polymorphisms predictive of DWG in addition to those obtained from the stepwise and the forward procedure. These polymorphisms are: LEPRK109R (P ¼ 0.05) and LEPRQ223R (P ¼ 0.02). However, they were not retained in the final predictive models of DWG because their contribution was considered marginal and the first two regression procedures discarded these polymorphisms. Table 3 presents results from the stepwise regression procedure only.
Discussion
In this study, 15 genetic polymorphisms in 10 obesity candidate genes were tested for their capacity to predict adiposity gain over periods ranging, on average, between 6-10 years. The variant alleles have been associated with obesity-related phenotypes in previous studies (mostly in more than five studies) 3 and were known to modulate transcription and/or protein levels or to change affinity for a ligand ( Table 1 ). The results show that the variant alleles (except for GCCR) in these obesity candidate genes contribute to adiposity changes over time, which suggests that these genes are playing an important role in determining increases in adiposity. Abbreviations: DBMI ¼ delta-BMI; DSUM6 ¼ delta-sum of six skinfolds; DWG ¼ delta-waist girth, DWGBMI ¼ delta-waist girth (adjusted for initial BMI and DBMI); DFM ¼ delta-fat mass; DPFAT ¼ delta-%body fat; IV ¼ independent variables; R 2 ¼ partial and total variance (%); and NC ¼ no significant contribution. All phenotypes were adjusted for gender, initial age, initial dependent variable measures and Dage but DWGBMI was adjusted for gender, initial age, initial BMI and initial WG measure and Dage and DBMI. Polymorphisms that showed significant association (Po0.05) are in bold.
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Longitudinal data available for the genetic study of human FM gain (obesity development) are limited. Although QFS have well standardized obesity phenotypes (FM and PFAT in this case) and a quite long follow-up (between 6 and 10 years) for this kind of study, the number of subjects remains moderate. However, the fact that the same genes were consistently retained within different models for comparable phenotypes, which is particularly true for LEP, ADRb3 and NMB genes, gives us confidence in the suggested models despite the fact that the P-values are marginal for most polymorphisms. In a multigenic condition like obesity, it is expected that a single-gene polymorphism has only a small effect on the phenotype. However, as shown in the present study, when several genes are considered simultaneously, a significant fraction of the variance can be accounted for, despite the fact that each gene, taken individually, does not necessarily contribute to the phenotypic variance to a significant extent.
Of the 15 candidate gene polymorphisms selected to test for association with changes in body fatness only 3-5 genes were retained in each models and explained a significant amount of the variance in body fat changes over time. As body fatness changes were adjusted for the initial value of the phenotype, the genes identified could be considered as important determinants of changes in body fatness with age, independent of their effects on the initial value of phenotype per se. Aging was also associated with decrease energy expenditure greater than the decrease in energy intake leading to positive energy balance and obesity. It is thus possible that changes in adiposity could be partly accounted for by changes in energy expenditure. We have tested that by computing correlations between changes in resting metabolic rate (adjusted for sex, age, duration of follow-up and initial value of resting metabolic rate) and changes in adiposity and found significant (Po0.01) correlations ranging from 0.26 for DSUM6 to 0.30 for DFM. These data suggest that less than 10% of the variance in adiposity changes can be accounted for by changes in energy expenditure.
As the age distribution is representative of two groups (740 years of age) corresponding to the two generation in QFS, the stepwise regression analyses were repeated by stratifying on age group to verify whether the observed associations differed in younger versus older individuals. Except for DBMI for which significant results were obtained only in subjects below 40 years of age, all other models showed a significant contribution of gene(s) in determining adiposity changes in both age groups. The variance in adiposity changes accounted for by the candidate genes was about two times higher in the younger age group than in the older age group (see Table 3 ), suggesting that these genes may be more important in determining adiposity changes before 40 years of age. Our results also suggest that different genes may act at different ages, as the genes associated with adiposity changes were different depending on the age group. However, one should keep in mind that these results should be interpreted with caution, as the number of subjects in each age group is limited ((131pnp175). Table 4 presents a summary of the results (based on whole sample analyses) for each phenotype along with suggested ranking for the effects of the genes on adiposity changes based on the magnitude of their contributions (P-value) and the number of times the gene was retained in a model. LEP is the gene that affects most the adiposity changes in this study. The effects of LEP on food intake and energy expenditure are well known but its global role in human obesity is still controversial. This is probably mainly due to its limitation to induce weight loss when used as a treatment for obesity (except in LEP deficiency) 31 and to hyperleptinemia and an apparent LEP resistance syndrome in human obesity. As shown in Table 1 , the LEP-38 polymorphism was associated with LEP levels in obese individuals. In that study, the carriers of the g.À38G were associated with lower LEP levels. 23 In the present study, LEP g.À38G homozygotes gained more FM as compared to the g.À38A homozygotes (genotype, 1s means7standard error: A/A, 2.170.9; A/G, 3.270.6 and G/G, 4.470.7; P ¼ 0.03). This finding is in accordance with the anorexic and increased energy expenditure effects of increased LEP levels on energy metabolism as the G/G have been shown to have lower LEP levels. 23 Moreover, and as we have reported recently, 11 homozygotes for the threonine allele of the NMB gene gained higher amount of FM over time as compared to the other genotypes. Finally, carriers of the arginine for ADRB3W64R polymorphism gained less FM as compared to tryptophan homozygous. Interestingly, genes that were predictive of adiposity changes-related phenotypes explained, in most models except for DWGBMI, a similar fraction of the variance as compared to the common covariates. The best example is changes in FM for which the common covariates explained 7.5% of the variance as compared to genetic information, which explained 8.5% of the residual variance. This suggests that the effects of genetic factors on adiposity changes over time are just as important as accepted risk factors of obesity (age, gender and initial value of FM). Although this study is incomplete in term of covariates, genes tested, the number of subjects and the duration of the follow-up, it indicates that genetic information significantly improve our capacity to predict adiposity changes, especially when several genes are considered simultaneously. The identification of genes associated with gains in adiposity with age could have important clinical relevance. Indeed, it could allow to identify individuals carrying an increased genetic risk to develop obesity with age and would make it possible to develop early targeted preventive interventions.
In summary, genetic polymorphisms in candidate genes of obesity accounted for a significant portion of the variance in adiposity changes over time with a range from 3.1 to 8.5% for DBMI and for DFM, respectively. The LEP gene is the strongest predictor of FM gain explaining up to 3.3% of the variance in the gain of percentage body fat. Our results also suggest that genes contributing to adiposity changes are Candidate genes of adiposity changes L Bouchard et al different, and their effects stronger, in younger (o40 years) compared with older (X40 years) subjects. Finally, this study shows that genetic information is useful for the identification of individuals at high risk for gaining body fat over time. The results of this study suggest that genetic information could be useful to consider, in addition to traditional risk factors of weight gain, in the prevention and treatment of obesity, including intervention study (such as weight loss program), as it can increase our understanding of the etiology of obesity. Overall, LEP, NMB and the ADRB3 genes were the most consistent predictors of the changes in adiposity taking place over the years in adult subjects. Abbreviations: ADR, adrenergic receptor; DBMI, delta-body mass index; DFM, delta-fat mass; DPFAT, delta-%body fat; DSUM6, delta-sum of six skinfolds; DWG, delta-waist girth, DWGBMI, delta-waist girth (adjusted for first BMI and DBMI); GCCR, glucocorticoid receptor; GNB3, guanine nucleotide binding protein b3; LEP, leptin; LEPR, leptin receptor; NC, no significant contribution; PPARg, peroxisome proliferator-activated receptor-g; TNF-a, tumor necrosis factor-a. All phenotypes were adjusted for gender, initial age, initial dependent variable measures and Dage but DWGBMI was adjusted for gender, initial age, initial BMI and initial WG measure and Dage and DBMI. Polymorphisms that showed significant association (Po0.05) are in bold.
